ARWR asking 5.03
Arrowhead Research Corporation, a development stage company, operates as a nanotechnology company. The company, through its subsidiary, Aonex Technologies, Inc., commercializes a method for manufacturing semiconductor nanomaterials. It develops Cyclosert, a proprietary drug delivery platform technology based on a nano-engineered class of linear cyclodextrin-containing polymers, which are nontoxic and nonimmunogenic, through its subsidiary, Insert Therapeutics, Inc. The company also conducts preclinical animal tests of IT-101, the camptothecin-Cyclosert conjugate. Arrowhead designs, develops, and commercializes novel RNA interference therapeutics to treat diseases and other medical conditions, through its subsidiary, Calando Pharmaceuticals, Inc. In addition, the company, through its subsidiary, NanoPolaris, Inc. licenses intellectual property to customers who utilize nanotube technology in their products. NanoPolaris also controls commercialization of issued patents and patent applications claiming nanotube compositions of matter and general manufacturing techniques, such as chemical vapor deposition synthesis; plasma chemical vapor deposition synthesis; and purification, solubilization, separation of certain types of tubes, coating, functionalization, and manipulation.
 |
